Estrogen receptor β: Putting a positive into triple negative breast cancer?

Hormone Molecular Biology and Clinical Investigation

Volumn 16, Issue 3, 2013, Pages 117-123

  Smart, Emily ^a   Hughes, Thomas ^b   Smith, Laura ^a   Speirs, Valerie ^a  

^a ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^b UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

Biomarker; Estrogen receptor ; Tamoxifen; Triple negative breast cancer

Indexed keywords

BIOLOGICAL MARKER; BRCA1 PROTEIN; BRCA2 PROTEIN; CLAUDIN 3; CLAUDIN 4; CLAUDIN 7; CYCLIN A; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; ESTROGEN RECEPTOR BETA 1; ESTROGEN RECEPTOR BETA 5; MESSENGER RNA; TAMOXIFEN; UNCLASSIFIED DRUG; UVOMORULIN;

BASAL LIKE BREAST CANCER; CANCER HORMONE THERAPY; CANCER SURVIVAL; CELL ADHESION; CELL INVASION; CELL MIGRATION; CELL MOTILITY; CORRELATION ANALYSIS; DISEASE FREE SURVIVAL; EPITHELIAL MESENCHYMAL TRANSITION; GENE MUTATION; HUMAN; OVERALL SURVIVAL; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECURRENCE FREE SURVIVAL; REVIEW; SURVIVAL RATE; TRIPLE NEGATIVE BREAST CANCER;

EID: 84928650305     PISSN: 18681883     EISSN: 18681891     Source Type: Journal    
DOI: 10.1515/hmbci-2013-0042     Document Type: Review

References (21)

1. Kuiper GG, Enmark E, Pelto-Huikko M, Nilsson S, Gustafsson J-Å. Cloning of a novel estrogen receptor expressed in rat prostate and ovary. Proc Natl Acad Sci USA 1996;93:5925-30. (Pubitemid 26190778)
2. Moore JT, McKee DD, Slentz-Kesler K, Moore LB, Jones SA, Horne EL, Su JL, Kliewer SA, Lehmann JM, Willson TM. Cloning and characterization of human estrogen receptor beta isoforms. Biochem Biophys Res Commun 1998;247:75-8. (Pubitemid 28412528)
3. Zhao C, Dahlman-Wright K, Gustafsson JA. Estrogen signaling via estrogen receptor {beta}. J Biol Chem 2010;285:39575-9.
4. Paruthiyil S, Parmar H, Kerekatte V, Cunha GR, Firestone GL, Leitman DC. Estrogen receptor beta inhibits human breast cancer cell proliferation and tumor formation by causing a G2 cell cycle arrest. Cancer Res 2004;64:423-8. (Pubitemid 38114127)
5. Warner M, Gustafsson JA. The role of estrogen receptor beta (ERbeta) in malignant diseases-a new potential target for antiproliferative drugs in prevention and treatment of cancer. Biochem Biophys Res Commun 2010;396:63-6.
6. Lazennec G, Bresson D, Lucas A, Chauveau C, Vignon F. ER beta inhibits proliferation and invasion of breast cancer cells. Endocrinology 2001;142:4120-30. (Pubitemid 32802685)
7. Hou YF, Yuan ST, Li HC, Wu J, Lu JS, Liu G, Lu LJ, Shen ZZ, Ding J, Shao ZM. ERbeta exerts multiple stimulative effects on human breast carcinoma cells. Oncogene 2004;23:5799-806. (Pubitemid 39093025)
8. Leung Y-K, Mak P, Hassan S, Ho S-M. Estrogen receptor (ER)-β isoforms: a key to understanding ER-β signaling. Proc Natl Acad Sci USA 2006;103:13162-7. (Pubitemid 44338933)
9. Mann S, Laucirica R, Carlson N, Younes PS, Ali N, Younes A, Li Y, Younes M. Estrogen receptor beta expression in invasive breast cancer. Hum Pathol 2001;32:113-8. (Pubitemid 32150637)
10. Honma N, Horii R, Iwase T, Saji S, Younes M, Takubo K, Matsuura M, Ito Y, Akiyama F, Sakamoto G. Clinical importance of estrogen receptor-beta evaluation in breast cancer patients treated with adjuvant tamoxifen therapy. J Clin Oncol 2008;26:3727-34.
11. Gruvberger-Saal SK, Bendahl PO, Saal LH, Laakso M, Hegardt C, Eden P, Peterson C, Malmstrom P, Isola J, Borg A, Ferno M. Estrogen receptor beta expression is associated with tamoxifen response in ERalpha-negative breast carcinoma. Clin Cancer Res 2007;13:1987-94. (Pubitemid 46649864)
12. Poola I, Fuqua SA, De Witty RL, Abraham J, Marshallack JJ, Liu A. Estrogen receptor alpha-negative breast cancer tissues express significant levels of estrogen-independent transcription factors, ERbeta1 and ERbeta5: potential molecular targets for chemoprevention. Clin Cancer Res 2005;11:7579-85. (Pubitemid 41507721)
13. Skliris GP, Leygue E, Curtis-Snell L, Watson PH, Murphy LC. Expression of oestrogen receptor-beta in oestrogen receptor-alpha negative human breast tumours. Br J Cancer 2006;95:616-26. (Pubitemid 44325902)
14. Marotti JD, Collins LC, Hu R, Tamimi RM. Estrogen receptor-beta expression in invasive breast cancer in relation to molecular phenotype: results from the Nurses' Health Study. Mod Pathol 2010;23:197-204.
15. Skliris GP, Parkes AT, Limer JL, Burdall SE, Carder PJ, Speirs V. Evaluation of seven oestrogen receptor beta antibodies for immunohistochemistry, western blotting, and flow cytometry in human breast tissue. J Pathol 2002;197:155-62. (Pubitemid 34567602)
16. Weitsman GE, Skliris G, Ung K, Peng B, Younes M, Watson PH, Murphy LC. Assessment of multiple different estrogen receptorbeta antibodies for their ability to immunoprecipitate under chromatin immunoprecipitation conditions. Breast Cancer Res Treat 2006;100:23-31.
17. Carder PJ, Murphy CE, Dervan P, Kennedy M, McCann A, Saunders PT, Shaaban AM, Foster CS, Witton CJ, Bartlett JM, Walker RA, Speirs V. A multi-centre investigation towards reaching a consensus on the immunohistochemical detection of ERbeta in archival formalin-fixed paraffin embedded human breast tissue. Breast Cancer Res Treat 2005;92:287-93. (Pubitemid 41279638)
18. Fuqua SA, Schiff R, Parra I, Moore JT, Mohsin SK, Osborne CK, Clark GM, Allred DC. Estrogen receptor beta protein in human breast cancer: correlation with clinical tumor parameters. Cancer Res 2003;63:2434-9. (Pubitemid 36605180)
19. Novelli F, Milella M, Melucci E, Di Benedetto A, Sperduti I, Perrone-Donnorso R, Perracchio L, Venturo I, Nistico C, Fabi A, Buglioni S, Natali PG, Mottolese M. A divergent role for estrogen receptor-beta in node-positive and node-negative breast cancer classified according to molecular subtypes: an observational prospective study. Breast Cancer Res 2008;10:4.
20. Skliris GP, Carder PJ, Lansdown MR, Speirs V. Immunohistochemical detection of ERbeta in breast cancer: towards more detailed receptor profiling? Br J Cancer 2001;84:1095-8. (Pubitemid 32448508)
21. Shaaban AM, Green AR, Karthik S, Alizadeh Y, Hughes TA, Harkins L, Ellis IO, Robertson JF, Paish EC, Saunders PT, Groome NP, Speirs V. Nuclear and cytoplasmic expression of ERbeta1, ERbeta2, and ERbeta5 identifies distinct prognostic outcome for breast cancer patients. Clin Cancer Res 2008;14:5228-35.